암백신 시장 규모, 점유율과 동향 분석 보고서 : 백신 유형별, 적응증 유형별, 기술 유형별, 지역별, 부문 예측(2026-2033년)
Cancer Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Preventive Cancer Vaccine, Therapeutic Cancer Vaccine), By Indication Type, By Technology Type, By Region, And Segment Forecasts, 2026 - 2033
상품코드:1941887
리서치사:Grand View Research
발행일:2026년 01월
페이지 정보:영문 150 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
암 백신 시장 요약
세계의 암 백신 시장 규모는 2025년에 99억 3,000만 달러로 추정되며, 2033년까지 233억 1,000만 달러에 달할 것으로 예측됩니다.
2026-2033년 연평균 복합 성장률(CAGR) 11.30%를 나타낼 것으로 예측됩니다. 이러한 성장은 주로 전 세계 암 부담 증가, 면역요법 기반 치료법 채택 확대, mRNA, 수지상 세포 플랫폼, 개인 맞춤형 신항원 백신 등 백신 기술의 급속한 발전으로 인해 주도되고 있습니다.
암 백신 산업은 전 세계 암 부담 증가와 장기적인 치료 옵션으로서 면역요법에 대한 관심이 높아짐에 따라 빠르게 성장하고 있습니다. mRNA, DNA 플랫폼 등 백신 기술의 발전으로 기존 치료법보다 효과적으로 면역체계가 암 특이적 항원을 인식하고 종양세포를 파괴하도록 설계하는 능력이 크게 향상되었습니다.
특히 치료 옵션이 제한적인 고형암의 경우, 부작용을 줄이고 환자 예후를 개선할 수 있는 맞춤 치료를 원하는 제약사 및 학계 연구그룹의 투자 확대로 암 백신에 대한 관심이 더욱 높아지고 있습니다. 예를 들어 2026년 1월, 모더나와 머크가 공동 개발한 맞춤형 암 백신을 키트루다와 병용 투여한 결과, 고위험군 흑색종 환자에서 장기 추적관찰 기간 중 재발 또는 사망 위험이 지속적으로 감소하는 것으로 보고되었습니다. 이를 통해 백신 접근법에 대한 신뢰가 강화되어 추가 임상 개발 및 자금 조달이 진행되고 있습니다.
암 백신 산업의 또 다른 주요 성장 요인은 백신 후보물질의 정확성과 효능을 향상시키는 과학 기술 혁신의 급속한 발전입니다. 항원 동정, 새로운 항원 표적화, 계산생물학의 새로운 기술은 개별 종양의 고유한 유전자 프로파일에 맞는 백신 개발을 가능하게 하며, 이는 강력한 면역반응을 유발하는 데 있으며, 매우 중요합니다. 임상시험 파이프라인이 확대되고 있다는 것은 연구자들과 투자자들 사이에서 암 백신이 기존 치료가 어려웠던 암을 포함한 여러 암종에서 의미 있는 효과를 낼 수 있다는 확신이 커지고 있다는 것을 보여줍니다.
예를 들어 2025년 7월 플로리다 대학 연구진은 전임상 모델에서 종양에 대한 강력한 항암 면역 반응을 유도하는 실험용 mRNA 백신을 개발했습니다. 이는 차세대 백신의 가능성과 시장 성장을 지원하는 기술적 모멘텀을 모두 보여주는 성과입니다.
시장 성장은 지원적인 정책 환경, 암 예방 및 조기 발견에 대한 일반 대중의 인식 개선, 백신 전략과 연계된 새로운 진단 툴의 통합에 의해 촉진되고 있습니다. 정부 및 보건기관은 면역치료 연구에 대한 자금 지원을 강화하고 있으며, 생명공학 기업과 연구기관의 협력도 증가하는 추세입니다. 이를 통해 제품 개발 및 규제 승인 프로세스가 가속화되고 있습니다.
또한 COVID-19 팬데믹 상황에서 백신 플랫폼의 성공은 암을 포함한 다른 질병에 대한 mRNA 기술에 대한 신뢰를 강화하여 투자를 확대하고 연구를 임상 적용으로 빠르게 전환하는 데 기여하고 있습니다. 예를 들어 2025년 9월 러시아는 첨단 mRNA 기술을 이용해 개발한 새로운 암 백신 '엔테로믹스'가 임상 사용 준비가 완료되어 규제 당국의 승인 후 환자에게 무상으로 제공될 것이라고 발표했습니다. 이는 시장 확대를 촉진하는 기술적 진보와 정책적 지원을 모두 보여주는 사례입니다.
목차
제1장 조사 방법과 범위
제2장 개요
제3장 암 백신 시장 변수, 동향 및 범위
제4장 암 백신 시장 : 백신 유형별 비즈니스 분석
제5장 암 백신 시장 : 적응증 유형별 비즈니스 분석
제6장 암 백신 시장 : 기술 유형별 비즈니스 분석
제7장 암 백신 시장 : 지역별 추정·동향 분석
제8장 경쟁 구도
KSA
영문 목차
영문목차
Cancer Vaccine Market Summary
The global cancer vaccine market size was estimated at USD 9.93 billion in 2025 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. This growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy-based treatments, and rapid advancements in vaccine technologies such as mRNA, dendritic cell platforms, and personalized neoantigen vaccines.
The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option. Advances in vaccine technology, such as mRNA and DNA platforms, have significantly improved the ability to design vaccines that teach the immune system to recognize cancer-specific antigens and destroy tumor cells more effectively than traditional therapies.
Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited. For instance, in January 2026, Moderna and Merck reported that their personalized cancer vaccine used with Keytruda showed a sustained reduction in risk of recurrence or death in high-risk melanoma patients during long-term follow-up, reinforcing confidence in vaccine approaches and driving further clinical development and funding.
Another major growth factor in the Cancer Vaccine industry is the rapid pace of scientific innovation improving the precision and effectiveness of vaccine candidates. New techniques in antigen identification, neoantigen targeting, and computational biology have enabled vaccines to be tailored to the unique genetic profile of individual tumors, which is critical for triggering a robust immune response. The expanding pipeline of clinical trials demonstrates increasing confidence among researchers and investors that Cancer Vaccine can deliver meaningful benefits across multiple cancer types, including those historically difficult to treat.
For instance, in July 2025, Scientists at the University of Florida developed an experimental mRNA vaccine that triggered a strong anticancer immune response against tumors in preclinical models, highlighting both the promise of next-generation vaccines and the technological momentum supporting market growth.
Market growth is also propelled by supportive policy environments, increasing public awareness of cancer prevention and early detection, and the integration of novel diagnostic tools that work in tandem with vaccine strategies. Governments and health agencies have intensified funding for immunotherapy research, and collaborations between biotech firms and research institutions are becoming more common, which accelerates product development and regulatory approval pathways.
Moreover, the success of vaccine platforms during the COVID-19 pandemic has reinforced confidence in mRNA technology for other diseases, including cancer, leading to greater investment and quicker translation of research into clinical applications. For instance, in September 2025, Russia announced that its new cancer vaccine Enteromix, developed using advanced mRNA technology, was ready for clinical use and would be provided free to patients following regulatory approval, illustrating both the technological progress and policy support driving market expansion.
Global Cancer Vaccine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Cancer Vaccine market report based on vaccine type, indication type, technology type, and region:
Vaccine Type Outlook (Revenue, USD Million, 2021 - 2033)
Preventive Cancer Vaccine
Therapeutic Cancer Vaccine
Others
Indication Type Outlook (Revenue, USD Million, 2021 - 2033)
Prostate Cancer
Bladder Cancer
Melanoma
Cervical Cancer
Other
Technology Type Outlook (Revenue, USD Million, 2021 - 2033)
Recombinant Cancer Vaccine
Whole-cell Cancer Vaccine
Viral Vector and DNA Cancer Vaccine
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vaccine Type
1.2.2. Indication Type
1.2.3. Technology Type
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR's Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Cancer Vaccine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter's Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Cancer Vaccine Market: Vaccine Type Business Analysis
4.1. Vaccine Type Market Share, 2025 & 2033
4.2. Vaccine Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
4.4. Preventive Cancer Vaccine
4.4.1. Preventive Cancer Vaccine Market, 2021 - 2033 (USD Million)
4.5. Therapeutic Cancer Vaccine
4.5.1. Therapeutic Cancer Vaccine Market, 2021 - 2033 (USD Million)
4.6. Others
4.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Cancer Vaccine Market: Indication Type Business Analysis
5.1. Indication Type Market Share, 2025 & 2033
5.2. Indication Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication Type, 2021 to 2033 (USD Million)
5.4. Prostate Cancer
5.4.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
5.5. Bladder Cancer
5.5.1. Bladder Cancer Market, 2021 - 2033 (USD Million)
5.6. Melanoma
5.6.1. Melanoma Market, 2021 - 2033 (USD Million)
5.7. Cervical Cancer
5.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
5.8. Other
5.8.1. Other Market, 2021 - 2033 (USD Million)
Chapter 6. Cancer Vaccine Market: Technology Type Business Analysis
6.1. Technology Type Market Share, 2025 & 2033
6.2. Technology Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by technology type, 2021 to 2033 (USD Million)
6.4. Recombinant Cancer Vaccine
6.4.1. Recombinant Cancer Vaccine Market, 2021 - 2033 (USD Million)
6.5. Whole-cell Cancer Vaccine
6.5.1. Whole-cell Cancer Vaccine Market, 2021 - 2033 (USD Million)
6.6. Viral Vector and DNA Cancer Vaccine
6.6.1. Viral Vector and DNA Cancer Vaccine Market, 2021 - 2033 (USD Million)
6.7. Other Technologies
6.7.1. Other Technologies Market, 2021 - 2033 (USD Million)
Chapter 7. Cancer Vaccine Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2025 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Cancer Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Technology Type Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Technology Type Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Technology Type Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
7.5.1. Europe Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Technology Type Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Technology Type Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Technology Type Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Technology Type Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Technology Type Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Technology Type Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Technology Type Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Technology Type Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Technology Type Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Technology Type Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Technology Type Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Technology Type Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Technology Type Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Technology Type Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Technology Type Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Brazil Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Technology Type Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. Argentina Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Technology Type Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Technology Type Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Technology Type Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Technology Type Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
